581 related articles for article (PubMed ID: 15061384)
1. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
2. First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.
O'Brien TJ; Kidd RS; Richard CA; Ha NH; Witcher P; Tran LV; Barbour A; Tuck M; McIntosh SD; Douglas JN; Harralson AF
Clin Chim Acta; 2013 Sep; 424():73-5. PubMed ID: 23688605
[TBL] [Abstract][Full Text] [Related]
3. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
4. Warfarin dosing and cytochrome P450 2C9 polymorphisms.
Joffe HV; Xu R; Johnson FB; Longtine J; Kucher N; Goldhaber SZ
Thromb Haemost; 2004 Jun; 91(6):1123-8. PubMed ID: 15175798
[TBL] [Abstract][Full Text] [Related]
5. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
6. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin].
Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP
Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757
[TBL] [Abstract][Full Text] [Related]
7. [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients].
Siguret V; Gouin I; Golmard JL; Geoffroy S; Andreux JP; Pautas E
Rev Med Interne; 2004 Apr; 25(4):271-4. PubMed ID: 15050794
[TBL] [Abstract][Full Text] [Related]
8. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose.
Tanira MO; Al-Mukhaini MK; Al-Hinai AT; Al Balushi KA; Ahmed IS
Community Genet; 2007; 10(1):32-7. PubMed ID: 17167248
[TBL] [Abstract][Full Text] [Related]
9. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
[TBL] [Abstract][Full Text] [Related]
10. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
[TBL] [Abstract][Full Text] [Related]
11. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.
King BP; Khan TI; Aithal GP; Kamali F; Daly AK
Pharmacogenetics; 2004 Dec; 14(12):813-22. PubMed ID: 15608560
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
Zhang J; Tian L; Huang J; Huang S; Chai T; Shen J
Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
Siddiqi A; Khan DA; Khan FA; Naveed AK
Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
[TBL] [Abstract][Full Text] [Related]
15. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
[TBL] [Abstract][Full Text] [Related]
16. Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians.
Nahar R; Deb R; Saxena R; Puri RD; Verma IC
Pharmacol Rep; 2013; 65(1):187-94. PubMed ID: 23563037
[TBL] [Abstract][Full Text] [Related]
17. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
[TBL] [Abstract][Full Text] [Related]
18. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.
Gage BF; Eby C; Milligan PE; Banet GA; Duncan JR; McLeod HL
Thromb Haemost; 2004 Jan; 91(1):87-94. PubMed ID: 14691573
[TBL] [Abstract][Full Text] [Related]
19. Warfarin dose related to apolipoprotein E (APOE) genotype.
Kohnke H; Sörlin K; Granath G; Wadelius M
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):381-8. PubMed ID: 15952022
[TBL] [Abstract][Full Text] [Related]
20. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
